Aptose Biosciences (NASDAQ:APTO) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note released on Wednesday morning, Benzinga reports. They currently have a $23.00 price objective on the biotechnology company’s stock.

Other equities research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Aptose Biosciences from a hold rating to a sell rating in a report on Monday, March 18th. Piper Sandler decreased their target price on shares of Aptose Biosciences from $12.00 to $5.00 and set an overweight rating on the stock in a research report on Thursday, February 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $19.80.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $1.66 on Wednesday. The company has a market cap of $26.10 million, a PE ratio of -0.22 and a beta of 1.30. Aptose Biosciences has a 12 month low of $1.36 and a 12 month high of $9.90. The company has a 50-day simple moving average of $1.81 and a 200-day simple moving average of $2.34.

Institutional Investors Weigh In On Aptose Biosciences

Several hedge funds have recently modified their holdings of APTO. Annandale Capital LLC lifted its position in Aptose Biosciences by 40.0% during the third quarter. Annandale Capital LLC now owns 74,666 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 21,334 shares in the last quarter. Sigma Planning Corp acquired a new position in Aptose Biosciences during the third quarter valued at approximately $408,000. Citadel Advisors LLC lifted its position in Aptose Biosciences by 256.6% during the fourth quarter. Citadel Advisors LLC now owns 61,875 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 44,522 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc acquired a new position in Aptose Biosciences during the fourth quarter valued at approximately $32,000. Finally, DRW Securities LLC acquired a new position in Aptose Biosciences during the fourth quarter valued at approximately $5,158,000. 26.62% of the stock is owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.